Adamis pharmaceuticals doses first patients in phase 2/3 clinical trial for tempol in the treatment of covid-19

San diego, sept. 02, 2021 (globe newswire) -- adamis pharmaceuticals corporation (nasdaq: admp) today announced the initiation of patient dosing in the phase 2/3 clinical trial for tempol, an oral antiviral product candidate, in adult patients with confirmed covid-19 infection. in preclinical studies, tempol has been shown to have antiviral, anti-inflammatory and antioxidant activity. the trial is designed to enroll 248 patients.
ADMP Ratings Summary
ADMP Quant Ranking